Researchers from the University of Colorado Anschutz Medical Campus have identified a potential new immune checkpoint receptor that could lead to treatments for diseases such as lung and bowel cancer and autoimmune conditions including IBD.
Connexall offers integration and communication platform used by major health systems in the U.S. and Canada. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
A new study, out today in the Journal of Urban Health, finds that involuntary sweeps of homeless encampments in Denver were not effective in reducing crime. Click here to view original post Click Here to […]
BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor […]
Copyright © 2026 Biotech Networks
